SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on January 26, 2018, reporting an event that occurred on January 25, 2018. The filing addresses a corporate governance decision regarding the company's fiscal calendar. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly procedural and contains no financial performance data.
Material Changes
The Board of Directors approved a resolution to change the Company's fiscal year structure:
- Previous Structure: A 52/53-week fiscal year ending on the Saturday closest to December 31.
- New Structure: A calendar year ending on December 31.
- Transition: The current fiscal year is extended from December 29, 2018, to December 31, 2018.
- Future Reporting: Subsequent fiscal years will begin on January 1 and end on December 31. Quarterly results will now align with calendar quarters (ending March 31, June 30, September 30, and December 31).
Guidance, Outlook, and Risks
The filing states that no transition report is required because the change is not deemed a change in fiscal year under Rule 13a-10 or Rule 15d-10 of the Securities Exchange Act of 1934. This is because the new fiscal year commences within seven days of the prior fiscal year and begins with the end of the prior fiscal year. No other risks, contingencies, or management outlook were disclosed in this document.
Key Facts for Investor Verification
- Verify the impact of the fiscal year change on the comparability of future quarterly earnings reports.
- Confirm that the extension of the current fiscal year to December 31, 2018, does not alter the timing of upcoming dividend payments or debt covenants.
- Ensure future financial statements are analyzed against calendar-year periods rather than the previous 52/53-week periods.